InvestSMART

Clever Culture Systems Limited (ASX:CC5)

ALERT: Price-sensitive ASX Announcement for CC5
Current share price for CC5 : $0.021 -0.008 (-27.59%)+
Announcement
Release
28 Jan 2026 8:19AM
Price at Release
$0.029
Full Release
download
Summary
Clever Culture Systems Ltd (CCS), an Australian medical technology company, has released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ending 31 December 2025. The company reported significant progress with its APAS® Independence system, expanding its global installed base to 27 instruments. Notably, AstraZeneca increased its purchases to 11 instruments. The company achieved annual recurring revenues exceeding $1.0 million, supported by AI software licenses and maintenance services. CCS reported net cash inflows of $1.7 million for the quarter, with a cash balance of $3.1 million at the end of December. The company's debt was fully repaid, enhancing its financial stability. Future sales opportunities are promising, with potential sales to major pharmaceutical companies valued at over $45 million, thanks to ongoing evaluations and positive customer feedback presented at global conferences.
Key Points
  • Quarterly report for period ending 31 December 2025.
  • Expansion of APAS® Independence installed base to 27 globally.
  • AstraZeneca increases purchases to 11 APAS instruments.
  • Annual recurring revenues exceed $1.0 million.
  • Net cash inflow of $1.7 million with all debt repaid.
  • Cash balance of $3.1 million at the end of December 2025.
  • Future opportunities with potential sales over $45 million.
  • Positive customer feedback from AstraZeneca, Bristol Myers Squibb, and Pfizer.
  • Company's emphasis on science-led approach and customer collaboration.
  • Continued commercial momentum with new APAS® Independence sales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.